

# Synthesis of boronated phenylalanine analogues with a quaternary center for boron neutron capture therapy

Marek Zaidlewicz\*, Joanna Cytarska, Adam Dzielendziak, and Marta Ziegler-Borowska

*Department of Chemistry, Nicolaus Copernicus University, 87-100 Torun, Poland*

*E-mail: [zaidlevi@chem.uni.torun.pl](mailto:zaidlevi@chem.uni.torun.pl)*

**Dedicated to Professor Mieczyslaw Makosza on the occasion his 70<sup>th</sup> birthday**  
(received 01 Aug 03; accepted 29 Sept 03; published on the web 02 Oct 03)

---

## Abstract

2-Amino-2-methyl-3-(4-dihydroxyborylphenyl)propionic acid (**3**,  $\alpha$ -methyl-BPA) and 1-amino-3-(4-dihydroxyborylbenzyl)cyclobutanecarboxylic acid **4**, which are (4-dihydroxyborylphenyl)alanine (BPA) analogues containing a quaternary center, have been synthesized from 4-allylbromobenzene.  $\alpha$ -Methyl-BPA has also been prepared from D,L-alanine, and the route is suitable for the synthesis of  $\alpha$ -alkyl-BPA. Both **3** and **4** exhibit very similar  $R_f$  values indicating similar lipophilicities. The products have been prepared as potential boron carriers for Boron Neutron Capture Therapy.

**Keywords:** Boronic acids, boronated amino acids

---

## Introduction

Boron Neutron Capture Therapy (BNCT) is a binary therapy requiring selective accumulation of boron-10 in a tumor cell. Irradiation of such cells by thermal neutrons results in a nuclear reaction producing an  $\alpha$ -particle and lithium-7 ion of high energy destroying the cell.<sup>1-6</sup> Early studies revealed that selective accumulation of boron in a tumor cell and low levels of boron in the blood are crucial factors for the therapy. Consequently, over the years several classes of compounds have been examined as potential boron carriers for BNCT. These include amino acids, antibodies, antisense agents, carbohydrates, growth factors, liposomes, nucleosides, polyamines, porphyrins and thiols, often carrying higher borane or carborane cages to transport a sufficient amount of boron to a tumor cell.<sup>1-3,7-10</sup> Two compounds, (4-dihydroxyborylphenyl)alanine (BPA, **1**) and sodium mercaptoundecahydrododecaborate (BSH, **2**) have emerged from these studies, and are used in clinical practice.<sup>1-7</sup> At present, there is much interest in developing new efficient methods for the preparation of BPA.<sup>11-14</sup> Although it is a simple boronated amino acid, containing only one boron atom per molecule, it achieves concentrations of boron in a

tumor cell sufficient for the therapy. However, BPA and BSH are not ideal, since higher concentrations of boron are desirable. Consequently, the synthesis of BPA analogues, including boronated natural and unnatural amino acids and amino alcohols, is the subject of active research.<sup>15-21</sup> Recently, it was shown that amino acids, such as 1-aminocycloalkanoic acids, cross the blood brain barrier and localize in Glioblastoma Multiforme and metastatic malignant melanoma more avidly than BPA.<sup>22</sup> This observation prompted a search for BPA analogues and other boronic acids containing 1-aminocycloalkancarboxylic acid moiety.<sup>17-21</sup> Such boronated cyclic amino acids contain a quaternary carbon atom bonded to the amino acid functionality. It seemed interesting to compare the effect of such quaternary center incorporated in an acyclic moiety of BPA analogue with a representative cycloalkyl analogue as potential boron carriers for BNCT. Consequently, we decided to prepare 2-amino-2-methyl-3-(4-dihydroxyborylphenyl)propionic acid (**3**,  $\alpha$ -methyl-BPA), the simplest BPA analogue containing a quaternary center, and for comparison its cycloalkyl analogue, 1-amino-3-(4-dihydroxyborylbenzyl)cyclobutane-carboxylic acid **4**, (Figure 1).





Figure 1

## Results and Discussion

$\alpha$ -Methyl-BPA was prepared following two routes, from 4-allylbromobenzene **6** via hydantoin, and from D,L-alanine by deprotonation-benzylation. 1-(4-Bromophenyl)propan-2-one **9**, a convenient intermediate for the first route, was prepared starting from 1,4-dibromobenzene **5** in an overall 70% yield and >99% purity. Lower yield than might be expected results from competing formation of 1,4-diallylbenzene **7** in the first step, leading to a mixture of **5-7**. To suppress the formation of **7**, 4-bromophenylmagnesium bromide was prepared from **5** by the addition of reagents in a reversed order, and the amount of **7** decreased to 10-15%. Both products have very close boiling points and their separation by distillation is inconvenient. Consequently, a mixture of **6** and **7**, 86:14, was used for the oxymercuration-demercuration reaction. The product alcohol **8** was cleanly separated from the product diol by distillation, and was oxidized


with PCC to give **9** of >99% purity, (Scheme 1). Its ketalization followed by lithiation and transmetalation with triisopropoxyborane gave 1-(4-dihydroxyborylphenyl)propan-2-one **11**. Hydantoin **12**, readily formed under standard conditions by treatment of **11** with potassium cyanide and ammonium carbonate, crystallized with one molecule of water per two hydantoin molecules. Alkaline hydrolysis of **12** under carefully controlled conditions produced **3**, isolated in 68% yield. The hydrolysis conditions must be controlled since at lower temperature the reaction is not completed, whereas at higher temperatures deboronated products are formed.



Scheme 1


The second route to **3** required 4-bromomethylphenylboronic acid and D,L-alanine properly protected for the deprotonation step. Based on the literature reports,<sup>23,24</sup> 4-chlorobenzaldehyde was used to protect the amino group of D,L-alanine, and the carboxylic group was protected as a methyl or ethyl ester. Free radical bromination of *p*-tolylboronic acid **13** produced 4-chlorobenzaldehyde acid, however, dibromination was a competing reaction. The crude product was a mixture of **13**, mono- and dibrominated acids, its composition depending on the bromine/**13** ratio used. The starting acid could be separated by crystallization, however, the solubility of dibrominated acid in several solvents tried was lower than 4-bromomethylphenylboronic acid, and crystallization was not effective for purification. To circumvent the difficulty, **13** was esterified with ethylene glycol. Although bromination of the ester **14** gave also

a mixture of the unreacted starting ester, mono- and dibrominated esters, the monobrominated ester **15** of  $\geq 95\%$  purity was separated by vacuum distillation, and was used for the reaction with the carbanion generated by deprotonation of protected D,L-alanine with potassium bis(trimethylsilyl)amide (KHMDs). Treatment of the product **16** with 1M hydrochloric acid deprotected the amino and boronic acid groups to give **17**. Deprotection of the methyl ester required reflux with 6M hydrochloric acid. When ethyl ester was used deprotonation required refluxing for a longer time and the yield of **3** was lower.



## Scheme 2

The cyclobutyl analogue **4** of BPA was prepared starting from **6** via hydantoin **22** (Scheme 3), following the route recently used for the synthesis of such cyclobutyl analogues.<sup>17</sup> The addition of dichloroketene to **6** gave **18** which was reduced without isolation to 3-(4-bromobenzyl)cyclobutanone **19**. Lithiation of its ketal **20** and transmetalation with triisopropoxyborane followed by hydrolysis afforded 3-(4-dihydroxyborylbenzyl)cyclobutanone **21**. The ketone was transformed into the corresponding hydantoin **22** which crystallized with one molecule of water. <sup>1</sup>H and <sup>13</sup>C analysis showed a mixture of diastereomers. The mixture was hydrolyzed under carefully controlled conditions to give **4**, isolated by crystallization as a mixture of diastereomers.



Scheme 3

The above described boronated amino acids **3** and **4** exhibited very similar  $R_f$  values, 0.29 and 0.31, respectively, using as a mobile phase acetonitrile-methanol-water, 10:2:1.5. The result reflects a similar lipophilicity of **3** and **4**, and indicates that the methyl substituted quaternary center of **3** and the cyclobutyl ring of **4** have a similar effect. The compounds will be tested for BNCT. Lipophilicity of  $\alpha$ -alkyl-BPA can be controlled by the size of alkyl groups, and the compounds can be readily prepared by monoalkylation of glycine followed by the route shown in Scheme 2. The formation of diastereomers, observed for cycloalkyl analogues, is avoided since only one stereogenic center is present, and the synthesis can be modified to achieve enantioselectivity. Work on the synthesis of  $\alpha$ -alkyl-BPA is in progress.

## Experimental Section

**General Procedures.**  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra were recorded on a Varian Gemini 200 MHz, a Bruker AMX 300 MHz and a Varian Inova 500 MHz spectrometers.  $^{11}\text{B}$  NMR spectra were recorded on the Varian Gemini 200 instrument. IR spectra were recorded on a FT-IR Spektrum 2000 Perkin Elmer spectrometer. Microanalyses were performed by the Microanalyses

Laboratory, Institute of Organic Chemistry PAN, Warsaw. GC analyses were performed on a Hewlett Packard 5890 chromatograph equipped with a 30 m  $\times$  0.32 mm SPB-5 column, a 50 m  $\times$  0.32 mm Carbowax 20M column, and a 5 m  $\times$  0.53 mm HP-1 column. All glassware used for reactions with air sensitive compounds was dried at 150 °C for several hours, assembled hot, and cooled in a stream of nitrogen. Melting points were measured on a Boetius ESP4/SI, Carl Zeiss Jena, apparatus and are uncorrected.  $R_f$  values were determined using a horizontal TLC chamber and TLC plates Macherey-Nagel Polygram<sup>®</sup> SIL G/UV<sub>254</sub>, 0.20 mm layer.

**Materials.** A mixture of 4-allylbromobenzene (**6**) and 1,4-diallylbenzene (**7**), 86:14, was prepared from 1,4-dibromobenzene (**5**) by the literature procedure,<sup>25</sup> using reversed order of the addition of reagents in the preparation of 4-bromophenylmagnesium bromide. Methyl 2-[(4-chlorobenzylidene)amino]propionate was prepared from D,L-alanine methyl ester and 4-chlorobenzaldehyde.<sup>24</sup> 2-(4-Bromomethylphenyl)-[1,3,2]dioxaborolane (**15**) was prepared by bromination of 2-(4-tolyl)-[1,3,2]dioxaborolane (**14**).<sup>26</sup> Tetrahydrofuran was distilled from benzophenone ketyl prior to use. Diethyl ether and benzene were distilled from lithium tetrahydridoaluminate and were kept under nitrogen.

**1-(4-Bromophenyl)propan-2-ol (8).** Tetrahydrofuran (200 mL) was added to a stirred solution of mercury(II) acetate (76.48 g, 240 mmol) in water (200 mL). The yellow mixture was stirred for 15 min and a mixture of **6** and **7** (45.83 g, 200 mmol of **6**) was added dropwise at room temperature. A clear colorless solution was formed. A 3M sodium hydroxide (200 mL, 600 mmol) was added followed with a solution of sodium borohydride (5.67 g, 150 mmol) in 3M sodium hydroxide (200 mL) at 20–25°C. After stirring for 3 h at room temperature, mercury was separated, and the mixture was saturated with sodium chloride. The organic layer was separated and the aqueous layer was extracted with diethyl ether (3  $\times$  50 mL). The extracts were combined with the organic layer, washed with saturated brine (2  $\times$  25 mL), dried with anhydrous potassium carbonate and finally with anhydrous magnesium sulfate. The product was isolated by distillation, 38.66 g, 90%, bp 93–95°C/0.3 mmHg. Lit.<sup>27</sup> bp 106°C/0.7 mmHg. NMR data:  $\delta_H$  (200 MHz, CDCl<sub>3</sub>) 1.22 (d,  $J$  = 6.0 Hz, 3H, CH<sub>3</sub>), 1.65 (s, 1H, OH), 2.64 (dd,  $J$  = 13.6 Hz,  $J$  = 5.4 Hz, 1H, CH<sub>2</sub>), 2.73 (dd,  $J$  = 13.6 Hz,  $J$  = 7.6 Hz, 1H, CH<sub>2</sub>), 3.83 (sextet,  $J$  = 6.2 Hz, 1H, CH), 7.08 (d,  $J$  = 8.4 Hz, 2H, H<sub>Ar</sub>), 7.42 (d,  $J$  = 8.4 Hz, 2H, H<sub>Ar</sub>).  $\delta_C$  (CDCl<sub>3</sub>) 22.82 (CH<sub>3</sub>), 44.99 (CH<sub>2</sub>), 68.59 (C–O), 120.29 (C), 131.08 (CH), 131.50 (CH), 137.50 (C).

IR (film) cm<sup>-1</sup>: 3360 (sb, OH), 1070 (s, C–O), 820 (m, CH<sub>Ar</sub>), 790 (s, CH<sub>Ar</sub>).

**1-(4-Bromophenyl)propan-2-one (9).** Pyridinium chlorochromate (32.33 g, 150 mmol) was added in portions to a stirred solution of **8** (21.51 g, 100 mmol) in methylene chloride (300 mL) at 20–25°C. The mixture was stirred for 4 h and diethyl ether (300 mL) was added. The solution was decanted from precipitated chromium salts and filtrated through a silica gel pad (30 g) which was then washed with diethyl ether (50 mL). The product was isolated by distillation, 18.11 g, 85%, bp 80–81°C/0.2 mmHg, mp 24–25°C. Lit.<sup>28</sup> bp 139°C/11 mmHg.

NMR data:  $\delta_{\text{H}}$  (200 MHz,  $\text{CDCl}_3$ ) 2.17 (s, 3H,  $\text{CH}_3$ ), 3.66 (s, 2H,  $\text{CH}_2$ ), 7.07 and 7.46 (4H, an AA'XX' system of *para* disubstituted benzene).  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ) 29.32 ( $\text{CH}_3$ ), 50.01 ( $\text{CH}_2$ ), 121.02 (C), 131.08 ( $2 \times \text{CH}$ ), 131.73 ( $2 \times \text{CH}$ ), 133.07 (C), 205.34 (C=O).

**1-(4-Bromophenyl)propan-2-one ethylene ketal (10).** A mixture of **9** (14.82 g, 70.0 mmol), ethylene glycol (18.6 mL, 300 mmol), *p*-toluenesulfonic acid (0.60 g, 3 mmol), and benzene (220 mL) was refluxed with a Dean-Stark trap for 21 h, and water (1.3 mL) was collected. The mixture was washed with 3M sodium hydroxide (5 mL), water (50 mL), and dried with magnesium sulfate. The product was isolated by distillation, 14.82 g, 82%, bp 89-90°C/1 mmHg. NMR data:  $\delta_{\text{H}}$  (200 MHz,  $\text{CDCl}_3$ ) 1.30 (s, 3H,  $\text{CH}_3$ ), 2.87 (s, 2H,  $\text{CH}_2$ ), 3.81 (m, 4H,  $\text{CH}_2$ , an AA'BB' system with 18 lines symmetrically placed about the center), 7.15 (d,  $J = 8.6$  Hz, 2H,  $\text{H}_{\text{Ar}}$ ), 7.40 (d,  $J = 8.6$  Hz, 2H,  $\text{H}_{\text{Ar}}$ ).  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ) 24.44 ( $\text{CH}_3$ ), 44.76 ( $\text{CH}_2$ ), 64.88 ( $2 \times \text{CH}_2$ ), 109.37 (C), 120.45 (C), 131.01 ( $2 \times \text{CH}$ ), 132.27 ( $2 \times \text{CH}$ ), 135.91 (C).

**1-(4-Dihydroxyborylphenyl)propan-2-one (11).** A 2.36M solution of *n*-butyllithium in hexanes (23.3 mL, 55.0 mmol) was added dropwise with stirring to a solution of **10** (12.90 g, 50.0 mmol) in tetrahydrofuran (150 mL) at -78°C under argon atmosphere, and the mixture was stirred for 2 h at this temperature. Triisopropoxyborane (12 mL, 51.0 mmol) was added dropwise and the mixture was left for 24 h at room temperature. It was cooled to 0°C, 2M hydrochloric acid (75 mL, 150 mmol) was added, and the mixture was stirred for 24 h at room temperature. The organic layer was separated and the aqueous layer was extracted with diethyl ether ( $3 \times 10$  mL). Solvents were removed and the remaining oil was dissolved in 2M sodium hydroxide, the solution was extracted with diethyl ether ( $2 \times 50$  mL), acidified with 3M hydrochloric acid, extracted with diethyl ether ( $3 \times 50$  mL) and the extract was washed with saturated brine (20 mL). Ether was removed and the product was obtained as a grey-white solid which was crystallized from ethyl acetate, 6.32 g, 71%, mp 195-196°C. NMR data:  $\delta_{\text{H}}$  (200 MHz,  $\text{CDCl}_3$ ) 2.20 (s, 3H,  $\text{CH}_3$ ), 3.80 (s, 2H,  $\text{CH}_2$ ), 7.38 (d,  $J = 10.0$  Hz, 2H,  $\text{H}_{\text{Ar}}$ ), 8.20 (d,  $J = 10.0$  Hz, 2H,  $\text{H}_{\text{Ar}}$ ).  $\delta_{\text{C}}$  ( $\text{CDCl}_3$ ) 29.39 ( $\text{CH}_3$ ), 51.26 ( $\text{CH}_2$ ), 129.11 ( $2 \times \text{CH}$ ), 136.07 ( $2 \times \text{CH}$ ), 138.95 (C), 205.81 (C=O).  $\delta_{\text{B}}$  ( $\text{CDCl}_3$ ) 30.63.

**1-(4-Dihydroxyborylphenyl)propan-2-one hydantoin (12).** A mixture of **11** (2.67 g, 15.0 mmol), 50% aqueous ethanol (45 mL), potassium cyanide (1.95 g, 30.0 mmol), and ammonium carbonate (6.82 g, 80.0 mmol) was placed in an autoclave and kept at 60°C for 4 h. The mixture was acidified with 6M hydrochloric acid, and filtered through a pad of activated carbon. Solvents were removed by evaporation at room temperature, and the solid material which remained was extracted with diethyl ether in a Soxhlet apparatus. A pale beige small crystals precipitated from the concentrated solution, 3.20 g, 83%, mp 211-215°C.

Anal. Calcd. for  $\text{C}_{11}\text{H}_{13}\text{BN}_2\text{O}_4 \cdot 0.5 \text{H}_2\text{O}$  (257.05): C, 51.39; H, 5.49; N, 10.90. Found: C, 51.38; H, 5.48; N, 10.56. NMR data:  $\delta_{\text{H}}$  (200 MHz, acetone- $d_6$ ) 1.50 (s, 3H,  $\text{CH}_3$ ), 2.91 (d,  $J = 13.0$  Hz, 1H,  $\text{CH}_2$ ), 3.11 (d,  $J = 13.0$  Hz, 1H,  $\text{CH}_2$ ), 7.04 (s, 1H, NH), 7.22 (d,  $J = 8.0$  Hz, 2H,  $\text{H}_{\text{Ar}}$ ), 7.78 (d,  $J = 8.0$  Hz, 2H,  $\text{H}_{\text{Ar}}$ ), 9.24 (s, 1H, NH).  $\delta_{\text{C}}$  (acetone- $d_6$ ) 23.73 ( $\text{CH}_3$ ), 43.48 ( $\text{CH}_2$ ), 63.86 (C), 129.62 ( $2 \times \text{CH}$ ), 134.10 ( $2 \times \text{CH}$ ), 137.85 (C), 155.76 (C=O), 177.32 (C=O).  $\delta_{\text{B}}$  (acetone- $d_6$ ) 33.96.

**2-Amino-3-(4-dihydroxyborylphenyl)-2-methylpropionic acid (3)**

**By hydrolysis of 12.** A mixture of **12** (0.80 g, 3.3 mmol) and a 2M sodium hydroxide solution (33 mL, 16.5 mmol) was placed in an autoclave and kept at 120°C for 2 h. After cooling, the mixture was treated with 4M hydrochloric acid to pH 6.5–7. The precipitated gelatinous solid was filtered off and washed with warm water (25 mL). The filtrate was concentrated under vacuum and the product crystallized out. Recrystallization from water gave 0.49 g, 68% pale beige crystals, mp 302–305°C (decomposition). NMR data:  $\delta_{\text{H}}$  (200 MHz, D<sub>2</sub>O/NaOD) 1.38 (s, 3H, CH<sub>3</sub>), 2.78 (d,  $J = 14.1$  Hz, 1H, CH<sub>2</sub>), 3.12 (d,  $J = 14.1$  Hz, 1H, CH<sub>2</sub>), 7.04 (d,  $J = 7.8$  Hz, 2H, H<sub>Ar</sub>), 7.45 (d,  $J = 7.8$  Hz, 2H, H<sub>Ar</sub>).  $\delta_{\text{C}}$  (D<sub>2</sub>O/NaOD) 24.76 (CH<sub>3</sub>), 44.92 (CH<sub>2</sub>), 62.06 (C), 129.86 (2 × CH), 132.74 (2 × CH), 134.27 (C), 180.56 (C=O).  $\delta_{\text{B}}$  (D<sub>2</sub>O/NaOD) 4.49.

**From D,L-alanine.** A solution of potassium bis(trimethylsilyl)amide (4.40 g, 21.0 mmol) in tetrahydrofuran (15 mL) was added dropwise with stirring to a solution of methyl 2-[(4-chlorobenzylidene)amino]propionate (4.80 g, 20.0 mmol) in tetrahydrofuran (20 mL) at -78°C, and the red-brown mixture was stirred for 15 min. A solution of **15** (4.82 g, 20.0 mmol) in tetrahydrofuran (20 mL) was added to the mixture at -78°C, stirring was continued for 3 h, and the mixture was allowed to warm to -10°C. Hydrochloric acid (60 mL, 60.0 mmol) was added below 0°C and the mixture was stirred overnight at room temperature. The mixture was alkalinized with 3M sodium hydroxide solution, and extracted with diethyl ether (2 × 50 mL). The aqueous layer was separated, acidified with 2M hydrochloric acid to pH 6.5–7.0, concentrated under vacuum, 6M hydrochloric acid (100 mL, 0.60 mol) was added, and the mixture was refluxed for 3 h. Hydrochloric acid was removed under vacuum at room temperature. The product was crystallized from water, 3.96 g, 90%, mp 302–305°C (decomposition).

<sup>1</sup>H, <sup>13</sup>C, and <sup>11</sup>B spectra were identical with the spectra described above.

**3-(4-Bromobenzyl)cyclobutanone (19).** A solution of trichloroacetyl chloride (16.8 mL, 150 mmol) and phosphorous oxychloride (14.0 mL, 150 mmol) in diethyl ether (70 mL) was added dropwise with stirring in 1 h to a mixture of **6** and **7** (22.91 g, 100 mmol of **6**), freshly prepared Cu-Zn couple<sup>29</sup> (13.10 g, 200 mmol), and diethyl ether (150 mL), under nitrogen atmosphere. The reaction mixture was stirred for 1 h at room temperature and then refluxed for 3 h. After cooling to room temperature it was filtered through a cellite pad which was then washed with diethyl ether (100 mL). The filtrate was washed with ice-water (50 mL), neutralized with saturated sodium bicarbonate solution (3 × 50 mL), washed with water (3 × 30 mL), saturated brine (30 mL), and dried with magnesium sulfate. Ether was removed and a brown liquid which was obtained was dissolved in acetic acid (35 mL). Zinc powder (13.07 g, 200 mmol) was added, and the mixture was stirred at room temperature for 30 min, and then was gently refluxed for 2 h. After cooling to room temperature it was filtered through a cellite pad which was washed with ethyl acetate (100 mL). The filtrate was concentrated under vacuum to remove most of acetic acid. Ethyl acetate (30 mL) was added, and the solution was washed with saturated sodium bicarbonate solution (25 mL), water (25 mL), saturated brine (25 mL), and



dried with magnesium sulfate. The product was isolated by distillation, 12.34 g, 52%, bp 140-142°C/2 mmHg,  $n_D^{20} = 1.5462$ .

Anal. Calcd. for  $C_{11}H_{11}BrO$  (239.11): C, 55.25; H, 4.64. Found: C, 56.02; H, 4.65.

NMR data:  $\delta_H$  (200 MHz,  $CDCl_3$ ) 2.70 (septet,  $J = 6.8$  Hz, 1H, CH), 2.84 (m, 4H,  $CH_2$ ), 3.12 (m, 2H,  $CH_2$ ), 7.06 and 7.42 (4H, an AA'XX' system characteristic for *para* disubstituted benzene).  $\delta_C$  ( $CDCl_3$ ) 24.82 (CH), 41.18 ( $CH_2$ ), 52.19 ( $CH_2$ ), 120.19 (C), 130.18 (2 × CH), 131.63 (2 × CH), 138.89 (C), 206.93 (C=O).

IR (film)  $cm^{-1}$ : 1770 (sb, C=O), 1480 (s, C=C<sub>Ar</sub>), 830 (m, CH<sub>Ar</sub>).

**3-(4-Bromobenzyl)cyclobutanone ethylene ketal (20).** A mixture of **19** (5.98 g, 25.0 mmol), ethylene glycol (6.20 mL, 100 mmol), *p*-toluenesulfonic acid (0.25 g, 1.33 mmol) and benzene (85 mL) was refluxed for 22 h with a Dean-Stark trap. The mixture was cooled, washed with 3M sodium hydroxide (5 mL), water (20 mL), saturated brine (20 mL), and dried with magnesium sulfate. Benzene was removed under vacuum and the product was isolated by crystallization from *n*-pentane, 6.11 g, 86%, mp 50–52°C.

Anal. Calcd. for  $C_{13}H_{15}BrO_2$  (283.16): C, 55.14; H, 5.34. Found: C, 55.18; H, 5.50.

NMR data:  $\delta_H$  (500 MHz,  $CDCl_3$ ) 2.00 (m, 2H,  $CH_2$ ), 2.28 (septet,  $J = 7.5$  Hz, 1H, CH), 2.37 (m, 2H,  $CH_2$ ), 2.69 (d,  $J = 7.5$  Hz, 2H,  $CH_2$ ), 3.84 (s, 4H,  $CH_2$ ), 6.99 (d,  $J = 8.5$  Hz, 2H, H<sub>Ar</sub>), 7.35 (d,  $J = 8.5$  Hz, 2H, H<sub>Ar</sub>).  $\delta_C$  ( $CDCl_3$ ) 26.06 (CH), 40.81 (2 ×  $CH_2$ ), 41.46 ( $CH_2$ ), 63.54 ( $CH_2$ ), 63.97 ( $CH_2$ ), 106.40 (C), 119.66 (C), 130.21 (2 × CH), 131.33 (2 × CH), 139.70 (C).

**3-(4-Dihydroxyborylbenzyl)cyclobutanone (21).** A solution of **20** (2.83 g, 10.0 mmol) in tetrahydrofuran (40 mL) was cooled to -78°C, and 2.5M *n*-butyllithium solution in hexanes (4.4 mL, 11.0 mmol) was added dropwise under argon atmosphere. The mixture was stirred at -78°C for 1 h, triisopropoxyborane (2.07 mL, 11.0 mmol) was added, and stirring was continued overnight at room temperature. After cooling to 0°C, 2M hydrochloric acid (11.0 mL, 22 mmol) was added and the mixture was stirred for 10 h at room temperature. The organic layer was separated and the aqueous layer was extracted with diethyl ether (20 mL). The combined organic solution was washed with saturated brine (20 mL) and dried with magnesium sulfate. Solvents were removed under vacuum and the product was isolated by crystallization from ethanol-water (1:1), 1.80 g, 88%, mp 162–165°C.

NMR data:  $\delta_H$  (200 MHz, DMSO) 2.65 (m, 1H, CH), 2.83 (m, 4H,  $CH_2$ ), 3.05 (m, 2H,  $CH_2$ ), 7.18 (d,  $J = 8.0$  Hz, 2H, H<sub>Ar</sub>), 7.69 (d,  $J = 8.0$  Hz, 2H, H<sub>Ar</sub>).  $\delta_C$  (DMSO) 24.48 (CH), 41.02 ( $CH_2$ ), 51.75 (2 ×  $CH_2$ ), 127.61 (2 × CH), 134.24 (2 × CH), 142.41 (C), 207.69 (C=O).  $\delta_B$  (AcOEt) 31.82.

IR (KBr)  $cm^{-1}$ : 3397 (sb, OH), 1766 (s, C=O), 1610 (m, CH<sub>Ar</sub>), 1342 (sb, B–O), 838 (mb, CH<sub>Ar</sub>).

**3-(4-Dihydroxyborylbenzyl)cyclobutanone hydantoin (22).** A mixture of **21** (2.04 g, 10.0 mmol), 30% ethanol (20.0 mL), potassium cyanide (1.30 g, 20.0 mmol), and ammonium carbonate (4.80 g, 50.0 mmol), was placed in an autoclave and kept at 60°C for 4 h. After cooling, the mixture was acidified with 4M hydrochloric acid. Ethanol and water were removed under vacuum and the product was crystallized from ethanol-water (1:20), 1.30 g, 95%, mp 256-258°C.

Anal. Calcd. for  $C_{13}H_{15}BN_2O_4 \cdot H_2O$  (292.11): C, 53.45; H, 5.87; N, 9.59. Found: C, 53.52; H, 5.90; N, 9.60.

NMR data of the major diastereomer:  $\delta_H$  (300 MHz, DMSO) 1.97 (m, 2H, CH), 2.20 (m, 2H, CH<sub>2</sub>), 2.39 (m, 1H, CH<sub>2</sub>), 2.66 (d,  $J = 6.9$  Hz, 2H, CH<sub>2</sub>), 7.11 (d,  $J = 8.1$  Hz, 2H, H<sub>Ar</sub>), 7.69 (d,  $J = 8.1$  Hz, 2H, H<sub>Ar</sub>), 7.98 (s, 2H, OH), 8.23 (s, 1H, NH), 10.55 (s, 1H, NH).  $\delta_C$  (DMSO) 27.74 (CH), 36.83 (CH<sub>2</sub>), 38.11 (CH<sub>2</sub>), 42.36 (CH<sub>2</sub>), 57.76 (C), 127.45 (2 × CH), 134.29 (2 × CH), 141.84 (C), 155.98 (C=O), 178.73 (C=O).

IR (KBr)  $cm^{-1}$ : 3311 (sb, OH), 2934 (m, CH), 1721 (s, C=O), 1610 (m, CH<sub>Ar</sub>), 1359 (sb, B–O), 1125 (m, C–O), 767 (mb, CH<sub>Ar</sub>).

**1-Amino-3-(4-dihydroxyborylbenzyl)cyclobutanecarboxylic acid (4).** To a degassed 2M sodium hydroxide solution (11.8 mL, 23.6 mmol) was added **22** (1.10 g, 4.02 mmol) and the mixture was refluxed for 2 h under nitrogen atmosphere. TLC analysis indicated no hydantoin. Activated carbon (0.52 g) was added and the mixture was filtered. The filtrate was neutralized with 6M hydrochloric acid. The precipitate which was formed was filtered off and crystallized from ethanol-water, 0.54 g, 54%, mp 280–282°C (decomposition).

NMR data of the major diastereomer:  $\delta_H$  (300 MHz, D<sub>2</sub>O, DCl, CD<sub>3</sub>OD) 1.69 (m, 2H, CH<sub>2</sub>), 2.4 (m, 3H, CHCH<sub>2</sub>), 2.55 (m, 2H, CH<sub>2</sub>), 7.24 (d,  $J = 7.8$  Hz, 2H, H<sub>Ar</sub>), 7.68 (d,  $J = 7.8$  Hz, 2H, H<sub>Ar</sub>)  $\delta_C$  (CD<sub>3</sub>OD) 29.22 (CH), 38.11 (2 × CH<sub>2</sub>), 42.06 (CH<sub>2</sub>), 59.85 (C), 128.86 (2 × CH), 135.11 (2 × CH), 146.85 (C), 179.82 (C=O).  $\delta_B$  (CD<sub>3</sub>OD) 23.55.

## Acknowledgements

Financial support from the Committee of Scientific Research, Warsaw, grant 6P05F 02320p03 is acknowledged.

## References

1. Soloway, A. H.; Tjarks, W.; Barnum, B. A.; Rong, F.-G.; Barth, R. F.; Codogni, I. M.; Wilson, J. G. *Chem. Rev.* **1998**, *98*, 1515.
2. Hawthorne, M. F. *Angew. Chem., Int. Ed.* **1993**, *32*, 950.
3. Hawthorne, M. F.; Madera, A. *Chem. Rev.* **1999**, *99*, 3421.
4. Sauerwein, W.; Zurlo A. *European J. Cancer.* **2002**, *38*, S31.
5. *Boron Neutron Capture Therapy for Tumors*, Hatanaka H. Ed., Niigata: Nishimura, 1986.
6. *Cancer Neutron Capture Therapy*; Mishima, Y. Ed.; Plenum Press: New York, 1996.
7. Coderre, J. A.; Elowitz, E. H.; Chadha, M.; Bergland, R.; Capala, J.; Joel, D. D.; Liu, H. B.; Slatkin, D. N.; Chanana, A. D. *J. Neuro-Oncology* **1997**, *33*, 141.
8. Lesnikowski, Z. J.; Shi, J.; Schinazi, R. F. *J. Organomet. Chem.* **1999**, *581*, 156.

9. Martin, B.; Posseme, F.; Le Barbier, C.; Carreaux, F.; Carboni, B.; Seiler, N.; Moulinoux, J.-P.; Delcros, J.-G. *Bioorg. Med. Chem.* **2002**, *10*, 2863.
10. Ghaneolhosseini, H.; Tjarks, W.; Sjoberg, S. *Tetrahedron* **1998**, *54*, 3877.
11. Nakamura, H.; Fujiwara, M.; Yamamoto, Y. *Bull. Chem. Soc. Japan* **2000**, *73*, 231.
12. Malan, Ch.; Morin, Ch. *J. Org. Chem.* **1998**, *63*, 8019.
13. Jung, E.; Lazarova, T. I. *J. Org. Chem.* **1999**, *64*, 2976.
14. Park, K. C.; Yoshino, K.; Tomiyasu, H. *Synthesis* **1999**, 2041.
15. Masunaga, S.-I.; Ono, K.; Kirihata, M.; Takagaki, M.; Sakurai, Y.; Kinashi, Y.; Kobayashi, T.; Nagasawa, H.; Uto, Y.; Hori, H. *Japn. J. Cancer Res.* **2001**, *92*, 996.
16. Takagaki, M.; Powell, W.; Sood, A.; Spielvogel, B. F.; Hosmane, N. S.; Kirihata, M.; Ono, K.; Masunaga, S.-I.; Kinashi, Y.; Miyatake, S.-I.; Hashimoto, N. *Radiation Res.* **2001**, *156*, 118.
17. Srivastava, R. R.; Singhaus, R. R.; Kabalka, G. W. *J. Org. Chem.* **1999**, *64*, 8495.
18. Srivastava, R. R.; Kabalka, G. W. *J. Org. Chem.* **1997**, *62*, 8730.
19. Srivastava, R. R.; Singhaus, R. R.; Kabalka, G. W. *J. Org. Chem.* **1997**, *62*, 4476.
20. Kabalka, G. W.; Das, B. C.; Das, S. *Tetrahedron Lett.* **2001**, *42*, 7145.
21. Das, B. C.; Das, S.; Li, G.; Bao, W.; Kabalka, G. W. *Synlett* **2001**, 1419.
22. Huber, K. S.; Thie, J. A.; Smith, G. T.; Kabalka, G. W.; Keller, I. B.; Cliefoth, A. B.; Campbell, S. K.; Buonocore E. *Clin. Positron Imaging* **1998**, *1*, 165.
23. O'Donnell, M. J.; Bennett, W. D.; Bruder, W. A.; Jacobsen, W.N.; Knuth, K.; LeClef, B.; Polt, R. L.; Bordwell, F. C.; Mrozack, S. R.; Cripe, T. A. *J. Am. Chem. Soc.* **1988**, *110*, 8520.
24. Mashchenko, N. V.; Matveeva, A. G.; Odinets, I. L.; Matrosov, E. I.; Petrov, E. S.; Terekhova, M. I.; Matveev, A. K.; Mastrjukova, T. A.; Kabachnik, M. I. *Zh. Obshch. Khim.* **1988**, *58*, 1973.
25. Jones, L. B.; Foster, J. P. *J. Org. Chem.* **1970**, *35*, 1777.
26. Kaminski, J. J.; Lyle, R. E. *Org. Mass Spectrom.* **1978**, *13*, 425.
27. Bays, D. E.; Foster, R. V. *US Pat. 3 647 881*; *Chem. Abstr.* **1970**, *73*, 66268.
28. Inaba, S.; Rieke, R. D. *J. Org. Chem.* **1985**, *50*, 1373.
29. Krepski, L. R.; Hassner, A. *J. Org. Chem.* **1978**, *43*, 2879.